Biomarker-directed first-line quadruplets in gastric cancer
Stomach cancer now has three add-on biomarkers (HER2, PD-L1, Claudin 18.2) that often overlap. Test whether combining two add-ons beats picking one.
About 20% of CLDN18.2-positive tumours are PD-L1 CPS ≥5; HER2 and CLDN18.2 rarely overlap. Chemotherapy + zolbetuximab + nivolumab is under study (ILUSTRO cohorts); HERIZON-GEA-01 already combined zanidatamab with tislelizumab.
Pages like this
not linked directly; found by shared links- PersonJeeyun Lee
Shares Zolbetuximab, Zanidatamab, Claudin 18.2, HER2.
- PersonYoon-Koo Kang
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Nivolumab.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonYelena Y. Janjigian
Shares CheckMate 649, HER2, Nivolumab, PD-1.
- PersonMin-Hee Ryu
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonKohei Shitara
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, HER2.
- PairingHER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd
Shares HERIZON-GEA-01, Zanidatamab, HER2, Gastric & gastro-oesophageal junction cancer.
- ProductCAPOX (capecitabine, oxaliplatin)
Shares CheckMate 649, SPOTLIGHT & GLOW, Gastric & gastro-oesophageal junction cancer.